User:Mr. Ibrahem/Leniolisib

Leniolisib, sold under the brand name Joenja, is a medication used to treat activated phosphoinositide 3-kinase delta syndrome (APDS). It is used in people at least 12 years old. It is taken by mouth.

Common side effects include headache, sinusitis, and atopic dermatitis. Use in pregnancy or breastfeeding may harm the baby. It should not be used in people with significant liver problems. It is a kinase inhibitor.

Leniolisib was approved for medical use in the United States in 2023. It received an orphan medication designation in Europe in 2020. In the United States it costs about 550,000 USD per year as of 2023. It is the first medication for APDS.